The journal retracts the 5 August 2022 article cited above.
Following publication, concerns were raised regarding the integrity of the images in the published figures and the validity of the data in the article.
Following provision of raw data by the authors, the Chief Editor concluded that the article’s conclusions and assertions were not sufficiently supported by the findings from the material provided; therefore, the article has been retracted. The authors did not agree to this retraction.
Summary
Keywords
miR-34a, PD-L1, Bladder cancer, Mesoporous silica nanoparticles, PLGA-PEG
Citation
Frontiers Editorial Office (2024) Retraction: Multicomponent siRNA/miRNA-loaded modified mesoporous silica nanoparticles targeted bladder cancer for a highly effective combination therapy. Front. Bioeng. Biotechnol. 12:1478191. doi: 10.3389/fbioe.2024.1478191
Received
09 August 2024
Accepted
16 August 2024
Published
21 August 2024
Approved by
Gianni Ciofani, Italian Institute of Technology (IIT), Italy
Volume
12 - 2024
Updates
Copyright
© 2024 Frontiers Editorial Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office, research.integrity@frontiersin.org
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.